Arena Looking To Puff Up Belviq Sales With Smoking Indication
This article was originally published in The Pink Sheet Daily
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
You may also be interested in...
With more than two years of competition behind them, it’s becoming clear that latecomer Contrave might just be the star of the obesity drug market, while its competitors are stuck playing second fiddle. Yet, all players are benefiting from increased obesity sales reps in the field.
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.
Orexigen and marketing partner Takeda’s efforts “will be scaled like a typical diabetes launch,” making it much larger than other recent obesity launches.